Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2008

View Archived Issues

Novel antibacterial agents reported in recent patent literature

Recent patents disclose new compounds for treating cancer

Neurogen suspends phase II/III insomnia study of adipiplon

Erythropoietin shows benefits for motoneuron degeneration treatment in preclinical studies

A novel positive allosteric modulator of nAChR7 under preclinical development for schizophrenia

European Commission grants orphan designation to Marqibo for ALL

Abraxis receives approval to market Abraxane for breast cancer in China

Amgen presents positive top-line denosumab results from phase III pivitol trial

Clinical results from blonanserin for the treatment of cognitive deficits in schizophrenia

Medarex provides updates on antibody development

Cardiome reports positive phase IIb data for oral vernakalant

FDA approves OncoGenex's SPA for phase III trial of OGX-011 in HRPC

NanoViricides reports excellent efficacy of EKC-Cide in first animal study

ValiRx to acquire Cronos Therapeutics

Edison's second-generation coenzyme Q10 analogue enters phase I clinical trials

Moderate efficacy of ARG-201 in patients with late-phase systemic sclerosis / News in Context

Luminex and ViroNovative sign license agreement for human metapneumovirus rights

Map commences phase III MAP-0004 trial in patients with migraine

Theravance presents clinical results from its LAMA Respiratory Program

FDA accepts Genta's amendment to NDA for Genasense in CLL as complete response

MRC and Biolex successfully complete collaboration to humanize BLX-301

Immunomedics enters worldwide license agreement with Nycomed for veltuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...